In Vitro and In Vivo Characterization of Novel Stable Peptidic Ghrelin Analogs: Beneficial Effects in the Settings of Lipopolysaccharide-Induced Anorexia in Mice
Language English Country Netherlands Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
29914876
DOI
10.1124/jpet.118.249086
PII: S0022-3565(24)26237-6
Knihovny.cz E-resources
- MeSH
- beta-Lactamases metabolism MeSH
- Ghrelin analogs & derivatives metabolism pharmacokinetics pharmacology MeSH
- Binding, Competitive MeSH
- Lipopolysaccharides adverse effects MeSH
- Mice, Inbred C57BL MeSH
- Mice MeSH
- Anorexia chemically induced drug therapy metabolism physiopathology MeSH
- Eating drug effects MeSH
- Receptors, Ghrelin metabolism MeSH
- Growth Hormone metabolism MeSH
- Amino Acid Sequence MeSH
- Signal Transduction drug effects MeSH
- Protein Stability MeSH
- Tissue Distribution MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- beta-Lactamases MeSH
- Ghrelin MeSH
- Lipopolysaccharides MeSH
- Receptors, Ghrelin MeSH
- Growth Hormone MeSH
Ghrelin, the only known orexigenic gut hormone produced primarily in the stomach, has lately gained attention as a potential treatment of anorexia and cachexia. However, its biologic stability is highly limited; therefore, a number of both peptide and nonpeptide ghrelin analogs have been synthesized. In this study, we provide in vitro and in vivo characterization of a series of novel peptide growth hormone secretagogue receptor (GHS-R1a) agonists, both under nonpathologic conditions and in the context of lipopolysaccharide (LPS)-induced anorexia. These analogs were based on our previous series modified by replacing the Ser3 with diaminopropionic acid (Dpr), the N-terminal Gly with sarcosine, and Phe4 with various noncoded amino acids. New analogs were further modified by replacing the n-octanoyl bound to Dpr3 with longer or unsaturated fatty acid residues, by incorporation of the second fatty acid residue into the molecule, or by shortening the peptide chain. These modifications preserved the ability of ghrelin analogs to bind to the membranes of cells transfected with GHS-R1a, as well as the GHS-R1a signaling activation. The selected analogs exhibited long-lasting and potent orexigenic effects after a single s.c. administration in mice. The stability of new ghrelin analogs in mice after s.c. administration was significantly higher when compared with ghrelin and [Dpr3]ghrelin, with half-lives of approximately 2 hours. A single s.c. injection of the selected ghrelin analogs in mice with LPS-induced anorexia significantly increased food intake via the activation of orexigenic pathways and normalized blood levels of proinflammatory cytokines, demonstrating the anti-inflammatory potential of the analogs.
References provided by Crossref.org
Lipidization as a tool toward peptide therapeutics
High-Fat Diet Induces Resistance to Ghrelin and LEAP2 Peptide Analogs in Mice